Drug Profile
CHO A04
Alternative Names: CHO-A04Latest Information Update: 28 Aug 2021
Price :
$50
*
At a glance
- Originator Academia Sinica
- Developer CHO Pharma
- Class Antineoplastics; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Cell death stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Aug 2021 No recent reports of development identified for preclinical development in Cancer in Taiwan (Parenteral)
- 20 Jul 2017 Preclinical trials in Cancer in Taiwan (Parenteral) (CHO Pharma pipeline, July 2017)
- 20 Jul 2017 CHO Pharma announces intention to submit IND for Cancer in 2018 (CHO Pharma pipeline, July 2017)